Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Open-label Clinical Study of Irinotecan Liposome Combined With Capecitabine, Bevacizumab and Camrelizumab as Second-line or Higher Treatment for Patients With Metastatic Colorectal Cancer

NCT07395063 is registered in ClinicalTrials.gov with The Fourth Affiliated Hospital of Zhejiang University School of Medicine as lead sponsor.

NCT NCT07395063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07395063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Open-label Clinical Study of Irinotecan Liposome Combined With Capecitabine, Bevacizumab and Camrelizumab as Second-line or Higher Treatment for Patients With Metastatic Colorectal Cancer
Lead sponsor
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase
Phase 2
Overall status
Not yet recruiting
Start date
February 1, 2026
Completion date
February 1, 2029
Enrollment
68 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer (crc)